Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

- January 22nd, 2018

Acasti Pharma (NASDAQ:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® for the treatment of severe hypertriglyceridemia, today announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares have given notice to exercise their over-allotment option … Continued

Acasti Pharma (NASDAQ:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® for the treatment of severe hypertriglyceridemia, today announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares have given notice to exercise their over-allotment option by purchasing an additional 766,179 common shares at a price of US$1.01 per share, for additional gross proceeds to Acasti of approximately US$773,000.
As quoted in the press release:

The Benchmark Company, LLC is acting as book-running manager of this Offering and as representative of the underwriters, The Benchmark Company, LLC and Dawson James Securities, Inc.

Click here to read the full press release.

  Life Science and Healthcare Investing in 2020 report cover

Life Science and Healthcare Investing in 2020

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2020 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply